SecBot SecBot
Biotech Drug Report Generated Aug 24, 2026

Dovato

GSK·GSK plc
NEUTRAL
Trial phase
Not stated
Time to market
Not stated
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

Dovato is a mature, approved product with no imminent FDA decision or pivotal readout, investors should watch quarterly ViiV/GSK HIV franchise sales for commercial momentum, and monitor competition from Gilead's Biktarvy and long-acting injectable therapies like Cabenuva (also ViiV). The next meaningful catalyst for GSK stock overall is more likely to come from a pipeline asset (e.g., depemokimab, blenrep data) than from Dovato specifically.

Price Chart

Loading chart...

Executive Summary

Dovato (dolutegravir/lamivudine) is an approved, once-daily, two-drug single-tablet regimen for HIV-1 infection, developed and marketed by ViiV Healthcare (majority-owned by GSK plc). It was first FDA-approved in April 2019 as the first complete two-drug regimen for treatment-naïve adults and later expanded to virologically suppressed patients switching therapy. As an already-approved, commercially marketed drug with no pending regulatory binary catalyst, Dovato contributes to GSK's HIV franchise revenue but does not represent a near-term binary share-price catalyst for the parent company.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report